{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05128942",
            "orgStudyIdInfo": {
                "id": "SPR001-205"
            },
            "organization": {
                "fullName": "Spruce Biosciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children With CAH",
            "officialTitle": "A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia",
            "therapeuticArea": [
                "Nephrology and Renal Diseases",
                "Other"
            ],
            "study": "a-phase-study-to-evaluate-the-safety-efficacy-and-pk-of-tildacerfont-in-children-with-cah"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-27",
            "studyFirstSubmitQcDate": "2021-11-09",
            "studyFirstPostDateStruct": {
                "date": "2021-11-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Spruce Biosciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "An investigation of the safety and efficacy of tildacerfont in participants with CAH.",
            "detailedDescription": "This is a study to evaluate the safety and efficacy of tildacerfont in participants with Congenital Adrenal Hyperplasia (CAH). Treatment will consist of 4 or 12 weeks of continuous dosing followed by safety follow up."
        },
        "conditionsModule": {
            "conditions": [
                "Congenital Adrenal Hyperplasia",
                "21-OHD"
            ],
            "keywords": [
                "Pediatric",
                "CAH",
                "Adrenal Disorder",
                "Congenital Adrenal Hyperplasia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Subjects will be assigned to treatment cohorts by age.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 55,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Age 11-17 Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 12 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 2: Age 11-17 Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 12 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 3: Age 2-10 Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 12 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 4: Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 4 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 5: Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 4 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 6: Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered twice daily for 4 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 7: Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 4 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 8: Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 4 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                },
                {
                    "label": "Cohort 9: Treatment with Tildacerfont",
                    "type": "EXPERIMENTAL",
                    "description": "Oral Tildacerfont administered daily for 4 consecutive weeks.",
                    "interventionNames": [
                        "Drug: Tildacerfont"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tildacerfont",
                    "description": "Oral tablet formulation taken once daily in combination with glucocorticoid therapy.",
                    "armGroupLabels": [
                        "Cohort 1: Age 11-17 Treatment with Tildacerfont",
                        "Cohort 2: Age 11-17 Treatment with Tildacerfont",
                        "Cohort 3: Age 2-10 Treatment with Tildacerfont",
                        "Cohort 4: Treatment with Tildacerfont",
                        "Cohort 5: Treatment with Tildacerfont",
                        "Cohort 6: Treatment with Tildacerfont",
                        "Cohort 7: Treatment with Tildacerfont",
                        "Cohort 8: Treatment with Tildacerfont",
                        "Cohort 9: Treatment with Tildacerfont"
                    ],
                    "otherNames": [
                        "SPR001"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Treatment-emergent adverse event (TEAE) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0",
                    "description": "To evaluate safety of tildacerfont in participants with CAH as measured by number of subjects with adverse events following dosing by CTCAE version 5.0",
                    "timeFrame": "12 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of participants who achieve a reduction in androstenedione (A4) or reduction in glucocorticoid (GC) dosing",
                    "description": "To determine the efficacy of tildacerfont on disease control or reduction of GC use in participants with classic CAH as measured by number of subjects who achieve a reduction in A4 or reduction in GC dosing during treatment period",
                    "timeFrame": "4 weeks or 12 weeks"
                },
                {
                    "measure": "Proportion of participants with elevated baseline A4 who achieve a reduction in A4",
                    "description": "To determine the efficacy of tildacerfont on disease control in participants with classic CAH measured by the number of participants with elevated baseline A4 who achieve reduction in A4 at week 4",
                    "timeFrame": "4 weeks"
                },
                {
                    "measure": "Proportion of participants with elevated baseline A4 who achieve a reduction in A4 who achieve A4 normalization",
                    "description": "To determine the efficacy of tildacerfont on disease control in participants with classic CAH measured by the number of participants with elevated baseline A4 who achieve reduction in A4 at week 4 or week 12",
                    "timeFrame": "4 weeks or 12 weeks"
                },
                {
                    "measure": "Tildacerfont pharmacokinetics (PK)",
                    "description": "To determine the consistency of preliminary tildacerfont PK in participants with those simulated in a PBPK model measured by comparing tildacerfont plasma concentrations with current PBPK simulation for consistency",
                    "timeFrame": "4 weeks or 12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female subjects aged 2+\n* Diagnosis of CAH due to 21-hydroxylase deficiency (OHD) and/or elevated 17- hydroxyprogesterone (OHP) requiring ongoing GC replacement since diagnosis\n* Stable dose of GC replacement for at least 1 month prior to screening\n\nExclusion Criteria:\n\n* History of bilateral adrenalectomy or hypopituitarism\n* Clinically significant unstable medical conditions, illness, or chronic diseases\n* History of active bleeding disorders\n* Females who are pregnant or nursing",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials",
                    "role": "CONTACT",
                    "phone": "415-655-4169",
                    "email": "CAHptain@sprucebiosciences.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Will Charlton, MD",
                    "affiliation": "Spruce Biosciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Spruce Study Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95821",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92123",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "WITHDRAWN",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55454",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Columbia",
                    "state": "South Carolina",
                    "zip": "29203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.00071,
                        "lon": -81.03481
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Fort Worth",
                    "state": "Texas",
                    "zip": "76104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.72541,
                        "lon": -97.32085
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Plano",
                    "state": "Texas",
                    "zip": "75093",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.01984,
                        "lon": -96.69889
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84113",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Charlottesville",
                    "state": "Virginia",
                    "zip": "22903",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.02931,
                        "lon": -78.47668
                    }
                },
                {
                    "facility": "Spruce Study Site",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23284",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000312",
                    "term": "Adrenal Hyperplasia, Congenital"
                },
                {
                    "id": "D000047808",
                    "term": "Adrenogenital Syndrome"
                },
                {
                    "id": "D000000308",
                    "term": "Adrenocortical Hyperfunction"
                },
                {
                    "id": "D000006965",
                    "term": "Hyperplasia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000012734",
                    "term": "Disorders of Sex Development"
                },
                {
                    "id": "D000014564",
                    "term": "Urogenital Abnormalities"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000000013",
                    "term": "Congenital Abnormalities"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000043202",
                    "term": "Steroid Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000000307",
                    "term": "Adrenal Gland Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10016",
                    "name": "Hyperplasia",
                    "asFound": "Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3664",
                    "name": "Adrenal Hyperplasia, Congenital",
                    "asFound": "Congenital Adrenal Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25853",
                    "name": "Adrenogenital Syndrome",
                    "asFound": "Congenital Adrenal Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3659",
                    "name": "Adrenal Gland Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M3660",
                    "name": "Adrenocortical Hyperfunction",
                    "asFound": "Adrenal Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15545",
                    "name": "Disorders of Sex Development",
                    "relevance": "LOW"
                },
                {
                    "id": "M12",
                    "name": "Congenital Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "M17314",
                    "name": "Urogenital Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25119",
                    "name": "Steroid Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T27",
                    "name": "21-hydroxylase Deficiency",
                    "asFound": "Congenital Adrenal Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1457",
                    "name": "Congenital Adrenal Hyperplasia",
                    "asFound": "Congenital Adrenal Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2879",
                    "name": "Hyperadrenalism",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M7992",
                    "name": "Epinephrine",
                    "relevance": "LOW"
                },
                {
                    "id": "M30371",
                    "name": "Racepinephrine",
                    "relevance": "LOW"
                },
                {
                    "id": "M211043",
                    "name": "Epinephryl borate",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}